

The Medicines Company

[View the current The Medicines Company Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/10209-The+Medicines+Company.html)

(<http://www.bioportfolio.com/bi corporate/10209-The+Medicines+Company.html>)

Contact Details:

One Cambridge Centre

Cambridge

MA

02142

United States of America

Tel: 617 225 9099

Fax:

Email: investor.relations@themedco.com

The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon angioplasty. The Company began selling ANGIOMAX in the United States in January 2001. The Company expects ANGIOMAX to be the cornerstone product of a planned acute hospital franchise. The Company is also developing a second product, CTV-05, a proprietary biotherapeutic agent with a potentially broad range of applications in the treatment of gynecological and reproductive infections.

Recent Publications by The Medicines Company:



- [Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.](#)
*Human serum albumin (HSA) did not affect oritavancin MICs against...*7th November, 2009
Anti-Infective Unit, The Medicines Company, St. Laurent, Quebec H4S 2A1,- *Diagn Microbiol Infect Dis.* 2009 Oct;65(2):207-10. ([DOI Direct Link](#))
- [Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.](#)
*The activity of oritavancin in vitro against recent clinical isolates of...*13th October, 2009
The Medicines Company, St Laurent, Quebec, Canada.- *Int J Antimicrob Agents.* 2009 Dec;34(6):550-4. Epub 2009 Oct 8. ([DOI Direct Link](#))
- [Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated methicillin-resistant Staphylococcus aureus \(MRSA\) isolates.](#)
*Human serum albumin (HSA) did not affect oritavancin MICs against...*12th September, 2009
The Medicines Company, 7170 Frederick Banting Street, Second Floor, Ville- *Int J Antimicrob Agents.* 2009 Sep 8. ([DOI Direct Link](#))

- [Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.](#)
*Oritavancin activity was tested against 15,764 gram-positive isolates...*10th September, 2009
The Medicines Company, 7170 Frederick Banting Street, Second Floor, Saint- Antimicrob Agents Chemother. 2009 Nov;53(11):4762-71. Epub 2009 Sep 8. ([DOI Direct Link](#))
- [Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.](#)
*Matriptase, also known as MT-SP1, is a type II transmembrane serine...*2nd September, 2009
The Medicines Company (Leipzig) GmbH, D-04103 Leipzig, Germany.- Int J Oncol. 2009 Aug;35(2):347-57.
- [Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.](#)
*A novel series of matriptase inhibitors based on previously identified...*16th June, 2009
The Medicines Company (Leipzig) GmbH, Deutscher Platz 5d, D-04103 Leipzig,- Bioorg Med Chem Lett. 2009 Apr 1;19(7):1960-5. Epub 2009 Feb 14. ([DOI Direct Link](#))
- [Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.](#)
*BACKGROUND: The optimal aspirin dose for the prevention of cardiovascular...*9th April, 2009
The Medicines Company, Balsberg, 8058 Zurich-Flughafen, Switzerland.- Ann Intern Med. 2009 Mar 17;150(6):379-86.
- [Sample size re-estimation for adaptive sequential design in clinical trials.](#)
*There is considerable interest in methods that use accumulated data to...*23rd January, 2009
Biostatistics, The Medicines Company, Parsippany, New Jersey 07054, USA.- J Biopharm Stat. 2008;18(6):1184-96. ([DOI Direct Link](#))
- [Assessing non-inferiority: a combination approach.](#)
*Non-inferiority designs are growing in importance as a strategy for...*25th April, 2008
The Medicines Company, 8 Campus Drive, Parsippany, NJ 07054, USA.- Stat Med. 2008 Feb 10;27(3):392-406. ([DOI Direct Link](#))
- [What is the proper activated clotting time \(ACT\) at which to remove a femoral sheath after PCI? What are the best "protocols" for sheath removal?](#)
*Non-inferiority designs are growing in importance as a strategy for...*13th July, 2005
The Medicines Company, Waltham, Mass, USA.- Crit Care Nurse. 2005 Apr;25(2):88-92, 94-5.
- [Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjects.](#)
*This study was designed to investigate the multiple-dose pharmacokinetics...*8th October, 2003
The Medicines Company, Gasstrasse 1, CH-4056 Basel, Switzerland.- Eur J Drug Metab Pharmacokinet. 2003 Jan-Mar;28(1):49-54.

Press Releases on The Medicines Company:

Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference	20th November, 2009	Centene Corporation	ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at the Bank of America Merrill Lynch 2009 Credit Conference, to be held December 2-3,
---	---------------------	---------------------	---

Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal	20th November, 2009	Cornerstone Therapeutics Inc.	CARY, N.C., Nov. 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products
Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results	20th November, 2009	Landauer, Inc.	GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- Landauer, Inc. (NYSE: LDR), will release financial results for the fiscal fourth quarter and full year of 2009 pre-market on Tuesday, December 1, 2009
Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost	20th November, 2009	Medco Health Solutions, Inc.	NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc (NYSE: MHS) is today contributing to a transformation in American healthcare through an advanced, wired pharmacy paradigm that
Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide,

BioNews Results for The Medicines Company



- [Merck Expresses Confidence in the Efficacy and Safety Profiles of ZETIA\(R\) \(ezetimibe\) and VYTORIN\(R\) \(ezetimi](#)
TradingMarkets: Nov 15 2009 11:18PM Matching: medicines company
- [The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patien](#)
Genetic Engineering News: Nov 15 2009 4:07PM Matching: medicines company
- [The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patien](#)
Genetic Engineering News: Nov 15 2009 2:16PM Matching: medicines company
- [The Medicines Company's Full Analysis of CHAMPION Phase III Data Shows Cangrelor Significantly Improves Patien](#)

- Freshnews.com: Nov 15 2009 2:09PM Matching: medicines company*
- [Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage](#)
Freshnews.com: Nov 13 2009 12:29AM Matching: medicines company
- [Genta Incorporated to Present at the Lazard Capital Markets Sixth Annual Healthcare Conference](#)
Pharma Live: Nov 10 2009 4:56PM Matching: medicines company
- [Bivalirudin Scores in Anticoagulation Study](#)
Pharmacy Practice News: Nov 10 2009 5:56PM Matching: medicines company
- [Bivalirudin Scores in Anticoagulation Study](#)
Pharmacy Practice News: Nov 10 2009 5:04PM Matching: medicines company
- [Genta Incorporated to Host Conference Call to Discuss Third Quarter 2009 Financial Results and Operational Priorities on November 16, 2009](#)
Yahoo! Canada: Nov 5 2009 9:39AM Matching: medicines company
- [ArQule Announces Third Quarter Fiscal 2009 Results](#)
SmartBrief: Nov 5 2009 4:45PM Matching: medicines company
- [ArQule Announces Third Quarter Fiscal 2009 Results](#)
Freshnews.com: Nov 5 2009 1:42PM Matching: medicines company
- [ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009](#)
News-Medical.Net: Nov 5 2009 1:16PM Matching: medicines company
- [Week of Nov. 2, 2009: Eli Lilly Opens Biotech Center; Johnson & Johnson Announces Restructuring; PPD Acquires](#)
Pharmaceutical Technology: Nov 5 2009 4:25PM Matching: medicines company
- [Drug Company-sponsored Events For Health Professionals Fail To Disclose Financial Ties](#)
Medical News Today: Nov 5 2009 11:06AM Matching: medicines company
- [Company and People Notes: Eli Lilly opens biotech center; Johnson & Johnson announces restructuring; PPD acquires Chinese CRO; and More](#)
Pharmaceutical Technology: Nov 5 2009 3:27AM Matching: medicines company

The Medicines Company Clinical Trials:



- [Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo

- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

